12:00 AM
Jan 26, 2015
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Anagrelide CR: Preliminary Phase II data

Preliminary data from an open-label, U.S. Phase II trial in 18 patients with elevated platelet counts secondary to essential thrombocythemia and other myeloproliferative neoplasms showed that twice-daily oral GALE-401 led to a confirmed or unconfirmed complete/partial platelet response in 9 patients. A complete platelet response was defined as...

Read the full 217 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >